97 related articles for article (PubMed ID: 23911227)
1. Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.
Lee J; Ou SH
Discov Med; 2013 Aug; 16(86):7-14. PubMed ID: 23911227
[TBL] [Abstract][Full Text] [Related]
2. Advances in targeted therapy for gastric cancer based on tumor driver genes.
Wu S; Xu P; Zhang F
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 53(1):73-83. PubMed ID: 38413217
[TBL] [Abstract][Full Text] [Related]
3. Beyond
Gkolfinopoulos S; Mountzios G
Ann Transl Med; 2018 Apr; 6(8):142. PubMed ID: 29862231
[TBL] [Abstract][Full Text] [Related]
4. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies.
Au TH; Wang K; Stenehjem D; Garrido-Laguna I
J Gastrointest Oncol; 2017 Jun; 8(3):387-404. PubMed ID: 28736627
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic target molecules for gastric and gastroesophageal junction cancer.
Kawakami H
Int J Clin Oncol; 2024 Apr; ():. PubMed ID: 38630383
[TBL] [Abstract][Full Text] [Related]
6. Leveraging synthetic lethality to uncover potential therapeutic target in gastric cancer.
Geng H; Qian R; Zhong Y; Tang X; Zhang X; Zhang L; Yang C; Li T; Dong Z; Wang C; Zhang Z; Zhu C
Cancer Gene Ther; 2024 Feb; 31(2):334-348. PubMed ID: 38040871
[TBL] [Abstract][Full Text] [Related]
7.
El Darsa H; El Sayed R; Abdel-Rahman O
J Exp Pharmacol; 2020; 12():349-361. PubMed ID: 33116950
[TBL] [Abstract][Full Text] [Related]
8. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
9. Innovative personalized medicine in gastric cancer: time to move forward.
Lee J; Kim KM; Kang WK; Ou SH
Clin Genet; 2014 Jul; 86(1):37-43. PubMed ID: 24749947
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancer.
Kuboki Y; Yamashita S; Niwa T; Ushijima T; Nagatsuma A; Kuwata T; Yoshino T; Doi T; Ochiai A; Ohtsu A
Ann Oncol; 2016 Jan; 27(1):127-33. PubMed ID: 26489445
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the HER2 targeted therapy of gastric cancer.
Matsuoka T; Yashiro M
World J Clin Cases; 2015 Jan; 3(1):42-51. PubMed ID: 25610849
[TBL] [Abstract][Full Text] [Related]
12. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Bilici A
World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies in gastroesophageal cancer.
Kasper S; Schuler M
Eur J Cancer; 2014 May; 50(7):1247-58. PubMed ID: 24495747
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?
Durães C; Almeida GM; Seruca R; Oliveira C; Carneiro F
Virchows Arch; 2014 Mar; 464(3):367-78. PubMed ID: 24487788
[TBL] [Abstract][Full Text] [Related]
15. Significant function and research progress of biomarkers in gastric cancer.
Ye DM; Xu G; Ma W; Li Y; Luo W; Xiao Y; Liu Y; Zhang Z
Oncol Lett; 2020 Jan; 19(1):17-29. PubMed ID: 31897111
[TBL] [Abstract][Full Text] [Related]
16. Novel Systemic Therapies for Advanced Gastric Cancer.
Kim HJ; Oh SC
J Gastric Cancer; 2018 Mar; 18(1):1-19. PubMed ID: 29629216
[TBL] [Abstract][Full Text] [Related]
17. Development of mesenchymal subtype gene signature for clinical application in gastric cancer.
Lee J; Cristescu R; Kim KM; Kim K; Kim ST; Park SH; Kang WK
Oncotarget; 2017 Sep; 8(39):66305-66315. PubMed ID: 29029513
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.
Kim SY; Ahn T; Bang H; Ham JS; Kim J; Kim ST; Jang J; Shim M; Kang SY; Park SH; Min BH; Lee H; Kang WK; Kim KM; Park W; Lee J
Oncotarget; 2017 Feb; 8(9):15014-15022. PubMed ID: 28122360
[TBL] [Abstract][Full Text] [Related]
19. Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis.
Ye P; Zhang M; Fan S; Zhang T; Fu H; Su X; Gavine PR; Liu Q; Yin X
PLoS One; 2015; 10(11):e0143207. PubMed ID: 26587992
[TBL] [Abstract][Full Text] [Related]
20. Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives.
Choi YY; Noh SH; Cheong JH
J Pathol Transl Med; 2016 Jan; 50(1):1-9. PubMed ID: 26498010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
